^
Association details:
| Biomarker: | FGFR4 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P75.07 - Association of FGFR4 Mutation With Immunotherapy Outcomes in Patients With Cancer
Published date:
01/12/2021
Excerpt:
Lung cancer patients in MSK-IMPACT...the immunotherapy efficacy of patients with FGFR4 mutations was significantly better…median progression-free survival was 13.2 months (95% CI, 0 to 27.3)...FGFR4 mutations are positively correlated with the efficacy of immunotherapy.
Source:
Title:
Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors
Published date:
01/06/2021
Excerpt:
Patients harbored FGFR4 mutations were found to have a better prolonged progression-free survival (PFS) to ICIs treatment (FGFR4: P = 0.0209).
DOI:
10.1186/s12967-020-02679-0
Source:
Title:
FGFR1-4 mutations are associated with immunotherapy outcomes in patients with non-small cell lung cancer
Published date:
04/19/2020
Excerpt:
These five independent cancer cohorts uncovered marked correlation between FGFR1-4 mutations and better immunotherapy outcomes in NSCLC population. Median progression-free survival was 13.2 months (95% CI, 9.1 to 17.3) in the FGFR1-4 mutations group and 3.8 months in the FGFR1-4 wild-type group (95% CI, 3.1 to 4.4) (hazard ratio for disease progression or death, 0.43; 95% CI, 0.30 to 0.62; P=0.0007). Median overall survival was 19.8 months (95% CI, 13.4 to 24.6) in the FGFR1-4 mutations group and 11.0 months (95% CI, 9.1 to 13.0) in the FGFR wild-type group (hazard ratio for death, 0.56; 95% CI, 0.36 to 0.89; P=0.03).
Source:
Title:
Special issue “The advance of solid tumor research in China”: FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer
Excerpt:
Sequencing data of an ICI-treated cohort were analyzed to identify genomic signatures predicting ICI efficacy….patients carrying FGFR4 alterations (FGFR4altered) had a better objective response rate (ORR) (50.0% vs 19.4%; P = .057) and improved median progression-free survival (mPFS) (13.17 vs 3.17 months; HR 0.37; 95% CI 0.14-1; P = .04) than wild-type patients (FGFR4wt)...FGFR4 alterations correlated with higher ORR (100% vs 31%; P = .028), longer median overall survival (mOS) (not reached [NR] vs 11 months; HR 0.28, 95% CI 0.09-0.89, P = .02), and mPFS (NR vs 6.07 months; HR 0.05, 95% CI 0-3.94, P = .039). FGFR4 alterations were confirmed as an independent predictor of superior PFS (P = .014) and OS (P = .005).
